Newsfeeds - Spark Newswire

1 minute read

Ipsen To Acquire Albireo For $42.00/Share Plus A Contingent Value Right Of $10.00/Share

Today, 6:46 PM

Ipsen (Euronext: IPN: ADR: IPSEY) and Albireo (Nasdaq: ALBO) today announced that they have entered into a definitive merger agreement under which Ipsen will acquire Albireo, a leading innovator in bile-acid modulators to treat pediatric and adult cholestatic liver diseases.

ALBO

1 minute read

Exelixis’ Cabometyx/Tecentriq Combo Misses Overall Survival Goal In Lung Cancer Setting

By Vandana Singh

Today, 6:46 PM

Exelixis Inc (NASDAQ: EXEL) announced that the CONTACT-01 study

EXEL

2 minute read

News

Ipsen Announced Onivyde Regimen Demonstrated Statistically Significant Improvement in Overall Survival in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma; Trial Met its Primary Endpoint and Key Secondary Endpoint

By Charles Gross

Today, 6:46 PM

Ipsen (Euronext: IPN; ADR: IPSEY) announced the Phase III NAPOLI 3 trial of Onivyde® (irinotecan liposome injection) plus 5 fluorouracil/leucovorin and oxaliplatin (NALIRIFOX regimen) met its primary endpoint demonstrating clinically meaningful and statistically significant improvement in overall survival compared to nab-paclitaxel plus gemcitabine in 770 previously untreated patients with metasta

IPSEY

6 minute read

Provention Bio’s Second Try, Apellis’s Eye Disorder Drug Review, 3 Adcom Verdicts And More: November’s Key PDUFA Catalysts Biotech Investors Must Know

By Shanthi Rexaline

Today, 6:46 PM

Editor's note: This story has been corrected to reflect that the FDA deferred action on Amicus Therapeutics' Biologics License Application.

APLS

4 minute read

AstraZeneca-Merck’s Prostate Cancer Combo Drug, 3rd Try For scPharma, 3 FDA Panel Decisions And More: October’s Key PDUFA Catalysts Biotech Investors Must Know

By Shanthi Rexaline

Today, 6:46 PM

Most FDA decisions scheduled for September yielded positive results, but there were stray disappointments as well. Seven new molecular entities, or NMEs, were approved during the month, taking the total NME approvals for the year to 24. This is far less than the 40 approvals received by the same time last year.

ALNY